ATE191567T1 - Bestimmung von nukleären matrixproteinen in flüssigkeiten - Google Patents

Bestimmung von nukleären matrixproteinen in flüssigkeiten

Info

Publication number
ATE191567T1
ATE191567T1 AT92925031T AT92925031T ATE191567T1 AT E191567 T1 ATE191567 T1 AT E191567T1 AT 92925031 T AT92925031 T AT 92925031T AT 92925031 T AT92925031 T AT 92925031T AT E191567 T1 ATE191567 T1 AT E191567T1
Authority
AT
Austria
Prior art keywords
matrix proteins
nuclear matrix
liquids
determination
evaluating
Prior art date
Application number
AT92925031T
Other languages
English (en)
Inventor
Lee Anne Beausang
Graham P Lidgard
Thomas E Miller
Original Assignee
Matritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matritech Inc filed Critical Matritech Inc
Application granted granted Critical
Publication of ATE191567T1 publication Critical patent/ATE191567T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT92925031T 1991-10-31 1992-10-29 Bestimmung von nukleären matrixproteinen in flüssigkeiten ATE191567T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78580491A 1991-10-31 1991-10-31
PCT/US1992/009220 WO1993009437A2 (en) 1991-10-31 1992-10-29 Nuclear matrix protein fluid assay

Publications (1)

Publication Number Publication Date
ATE191567T1 true ATE191567T1 (de) 2000-04-15

Family

ID=25136671

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92925031T ATE191567T1 (de) 1991-10-31 1992-10-29 Bestimmung von nukleären matrixproteinen in flüssigkeiten

Country Status (9)

Country Link
US (8) US5840503A (de)
EP (1) EP0642668B1 (de)
JP (1) JP3190042B2 (de)
AT (1) ATE191567T1 (de)
AU (1) AU658257B2 (de)
CA (1) CA2122473C (de)
DE (1) DE69230890T2 (de)
ES (1) ES2147555T3 (de)
WO (1) WO1993009437A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69230890T2 (de) * 1991-10-31 2000-12-07 Matritech, Inc. Bestimmung von nukleären matrixproteinen in flüssigkeiten
ES2214476T3 (es) * 1992-06-22 2004-09-16 Matritech, Inc. Nuevos marcadores de tipos celulares malignos de la matriz nuclear interior.
US5547928A (en) * 1993-12-17 1996-08-20 Matritech, Inc. Methods and compositions for the detection of colon cancers
US6280956B1 (en) 1995-11-03 2001-08-28 University Of Pittsburgh Antibodies to bladder cancer nuclear matrix proteins and their use
AU7474696A (en) * 1995-11-03 1997-05-22 Robert R. Bahnson Bladder nuclear matrix proteins and their use in detecting and treating cell proliferative disorders
US5914238A (en) 1996-06-05 1999-06-22 Matritech, Inc. Materials and methods for detection of breast cancer
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
US6232443B1 (en) * 1997-04-08 2001-05-15 University Of Pittsburgh Renal nuclear matrix proteins, polynucleotide sequences encoding them, and their use
US7229772B1 (en) 1998-03-18 2007-06-12 Roche Diagnostics Gmbh Detection of apoptotic products
ATE329264T1 (de) 1998-03-18 2006-06-15 Roche Diagnostics Gmbh Nachweis von produkten von apoptosis
IL146374A0 (en) 1999-05-17 2002-07-25 Pro Duct Health Inc Identifying material from a breast duct
US20030228640A1 (en) * 1999-10-15 2003-12-11 University Of Pittsburgh Nuclear matrix proteins, polynucleotide sequences encoding them, and their use
US6617432B1 (en) 1999-10-15 2003-09-09 University Of Pittsburgh Nuclear matrix proteins polynucleotide sequences encoding them and their use
KR100350111B1 (ko) 2000-02-22 2002-08-23 삼성전자 주식회사 반도체 장치의 배선 및 이의 제조 방법
US7654227B1 (en) * 2001-12-20 2010-02-02 Pat Yananton Absorbent pad for entrapping small and large particles, retaining liquids and eliminating odors
US7080373B2 (en) * 2001-03-07 2006-07-18 Freescale Semiconductor, Inc. Method and device for creating and using pre-internalized program files
US20030044352A1 (en) * 2001-04-24 2003-03-06 Phillips Nigel C. Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls
US7193065B2 (en) * 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
US20040018973A1 (en) * 2002-01-25 2004-01-29 University Of Pittsburgh Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
JP4274856B2 (ja) * 2003-06-19 2009-06-10 オリンパス株式会社 Ｄｎａとｄｎａ結合タンパク質との反応を検出する方法
KR20060087575A (ko) * 2003-09-23 2006-08-02 코닌클리즈케 필립스 일렉트로닉스 엔.브이. 필터 장치 및 필터링 방법
US7649988B2 (en) 2004-06-15 2010-01-19 Acoustic Technologies, Inc. Comfort noise generator using modified Doblinger noise estimate
US7935479B2 (en) 2004-07-19 2011-05-03 Cell Biosciences, Inc. Methods and devices for analyte detection
EP1776581B1 (de) * 2004-07-19 2015-05-06 ProteinSimple Verfahren zum Nachweis von Proteinen
US7846676B2 (en) * 2004-07-19 2010-12-07 Cell Biosciences, Inc. Methods and devices for analyte detection
EP1872139A2 (de) * 2005-04-09 2008-01-02 Cell Biosciences, Inc. Automatisches mikrovolumen-assaysystem
JP5421590B2 (ja) 2005-05-18 2014-02-19 ノバルティス アーゲー 自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法
US20070015166A1 (en) * 2005-07-14 2007-01-18 Nilsen Thor W Lateral flow methods and devices for detection of nucleic acid binding proteins
WO2007035864A2 (en) 2005-09-20 2007-03-29 Cell Biosciences, Inc. Electrophoresis standards, methods and kits
US20080017512A1 (en) * 2006-07-24 2008-01-24 Bordunov Andrei V Coatings for capillaries capable of capturing analytes
WO2008057605A2 (en) * 2006-11-10 2008-05-15 Quidel Corporation Nuclear protein extraction medium and method of use
US20090023156A1 (en) * 2007-07-20 2009-01-22 Voss Karl O Methods and reagents for quantifying analytes
US10107782B2 (en) 2008-01-25 2018-10-23 ProteinSimple Method to perform limited two dimensional separation of proteins and other biologicals
JP2011206049A (ja) 2010-03-08 2011-10-20 Sumio Sugano 壊死マーカー及びその用途
WO2013155634A1 (en) 2012-04-19 2013-10-24 Jiaqi Wu Dual wavelength isoelectric focusing for determining drug load in antibody drug conjugates
US9766206B2 (en) 2013-09-27 2017-09-19 ProteinSimple Apparatus, systems, and methods for capillary electrophoresis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4628027A (en) * 1982-05-19 1986-12-09 Molecular Engineering Associates, Ltd. Vitro diagnostic methods using monoclonal antibodies against connective tissue proteins
US4882268A (en) * 1985-12-24 1989-11-21 Massachusetts Institute Of Technology Method for determining tissue of origin and degree of malignancy of tumor cells
US5273877A (en) * 1985-12-24 1993-12-28 Massachusetts Institute Of Technology Non-histological cell type determination
US5032508A (en) * 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US4861581A (en) * 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US4937185A (en) * 1987-07-31 1990-06-26 The Ohio State University Research Foundation Detection of circulating antibodies to a cancer marker protein
WO1989006697A1 (en) * 1988-01-19 1989-07-27 The University Of Sydney Detection of cell death
US5017474A (en) * 1988-02-12 1991-05-21 Eastman Kodak Company Wash solution, test kit and method for the determination of an immunological ligand
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
ATE143056T1 (de) * 1990-05-01 1996-10-15 Isis Pharmaceuticals Inc Identifikation von neuen medikamenten und reagenzien
DE69230890T2 (de) * 1991-10-31 2000-12-07 Matritech, Inc. Bestimmung von nukleären matrixproteinen in flüssigkeiten
AU2890492A (en) * 1991-11-08 1993-06-07 University Of Saskatchewan Acute phase proteins for detection and prognosis of infection and tissue damage
AU4288593A (en) * 1992-04-15 1993-11-18 Brigham And Women's Hospital Method and composition for the detection of lesions
ES2214476T3 (es) * 1992-06-22 2004-09-16 Matritech, Inc. Nuevos marcadores de tipos celulares malignos de la matriz nuclear interior.

Also Published As

Publication number Publication date
EP0642668B1 (de) 2000-04-05
CA2122473C (en) 2001-01-23
EP0642668A1 (de) 1995-03-15
US20030096304A1 (en) 2003-05-22
US6410247B1 (en) 2002-06-25
DE69230890D1 (de) 2000-05-11
CA2122473A1 (en) 1993-05-13
WO1993009437A2 (en) 1993-05-13
US20060127941A1 (en) 2006-06-15
US20050059026A1 (en) 2005-03-17
US5989826A (en) 1999-11-23
US6162608A (en) 2000-12-19
US5840503A (en) 1998-11-24
JP3190042B2 (ja) 2001-07-16
AU658257B2 (en) 1995-04-06
US6740494B2 (en) 2004-05-25
JPH07500671A (ja) 1995-01-19
WO1993009437A3 (en) 1993-06-10
AU3123593A (en) 1993-06-07
DE69230890T2 (de) 2000-12-07
US5965376A (en) 1999-10-12
ES2147555T3 (es) 2000-09-16

Similar Documents

Publication Publication Date Title
ATE191567T1 (de) Bestimmung von nukleären matrixproteinen in flüssigkeiten
DE69033796D1 (de) Verfahren und gerät zum nachweis und zur quantifizierung von glukose in körperflüssigkeiten
ATE543T1 (de) Diagnostisches mittel, verfahren zu dessen herstellung sowie dessen verwendung zum nachweis von leukozyten in koerperfluessigkeiten.
DE69110098D1 (de) Teststreifen zur visuellen Bestimmung der Blutglucosekonzentration.
IT1230178B (it) Procedimento e dispositivo per l'analisi quantitativa e differenziale in profondita' di provini solidi con l'impiego di due raggi ionici
ATE263505T1 (de) Mittels vakuum verbesserter transdermaler flüssigkeitstransport
DE3880118D1 (de) Verwendung eines mittels in form von mikrokapseln zur schabenbekaempfung.
DE59007613D1 (de) Verfahren zum Nachweis und zur Bestimmung von Humanserumalbumin in biologischen Flüssigkeiten mit Hilfe fluorogener Cyanin-Farbstoffe.
DE68925481D1 (de) Verfahren zum nachweis von bakterien im harn
ATE97791T1 (de) Vorrichtung zur bestimmung der konzentration von zumindest einer in organischem gewebe vorliegenden substanz.
FI912050A0 (fi) Menetelmä ihmisen papilloomaviruksen (HPV) toteamiseksi diagnostista käyttöä varten
SE8701905L (sv) Foerfarande och kit foer diagnos av iga-nefropati
DE3888998D1 (de) Verfahren zur Bestimmung eines Antikörpers in menschlichen Körperflüssigkeiten.
DE69204157D1 (de) Verfahren zur bestimmung von anti-rns-antikörpern.
IT8921788A0 (it) Reattivo utile per la rilevazione e la determinazione quantitativa dei leucociti in fluidi biologici.
DE69428278D1 (de) Leukozytadhaesiontest
DK360186A (da) Diagnostisk fremgangsmaade til bedoemmelse af kliniske parametre ved direkte samling af biologiske materialer, og organ til udfoerelse af fremgangsmaaden
FI910324A7 (fi) Menetelmät ja testipakkaukset ihmisen leukosyyttiantigeeni-DNA:n havaitsemiseksi
ES8700440A1 (es) Metodo y equipo para detectar la presencia de aminas
DK70488D0 (da) Fremgangsmaade til paavisning af antistoffer i blod, samt membran og test-saet til anvendelse ved udoevelse af fremgangsmaaden
DE69013823D1 (de) Hydraulischer Fühler zum Nachweis und Lokalisierung des Quenchens in Supraleiter.
ATE130099T1 (de) Verfahren zum nachweis von antikörpern gegen streptokinase.
NO904548L (no) Paavisning, kvantifisering og klassifikasjon av ras-proteiner i kroppsfluider og -vev.
NO891535D0 (no) Metode for enkel paavisning og/eller kvantifisering av analytter i kroppsvaesker.
DE69402683D1 (de) Nachweis synthetischer oligonucleotide extrahiert aus körperflüssigkeiten oder geweben:

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner